Tag: Leukemia and Lymphoma

Risk scores predicting disease progression in early‐stage CLL: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy

AI SummaryThis study compares the accuracy of five different risk scores in predicting disease progression in early-stage chronic lymphocytic leukemia (CLL) patients. The risk scores showed similar discrimination, calibration, and parsimony, with CLL-IPI performing the best. Additionally, including IGHV subset 2 (IGHV2) as a poor prognostic parameter improved the accuracy of the risk scores. This… Continue reading Risk scores predicting disease progression in early‐stage CLL: Comparative analysis and usefulness of IGHV subset #2 to improve their accuracy

Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus

AI SummaryThe content describes the discovery of a human endogenous retrovirus (CT-RCC HERV-E) selectively expressed in clear cell renal cell carcinomas (ccRCC) and its use as an antigen for T cell-mediated killing. A novel T cell receptor (TCR) targeting a CT-RCC HERV-E-derived antigen specific to ccRCC was cloned and characterized for its antitumor activity. T… Continue reading Regression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus

[Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

AI SummaryThe article discusses the results of a phase 2 trial (MOLTO) on combining atezolizumab, venetoclax, and obinutuzumab in treating Richter transformation diffuse large B-cell lymphoma (DLBCL-RT). The study indicates that this chemotherapy-free regimen is effective and safe, potentially offering a new first-line treatment option for patients with DLBCL-RT.The atezolizumab, venetoclax, and obinutuzumab triplet combination… Continue reading [Articles] Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial

Lymphomas in the Young and the Old: How Do They Differ?

AI SummaryThe content discusses how Hodgkin lymphomas differ between young and old patients in terms of molecular characteristics. Research showed that younger patients had significantly more mutations and a faster accumulation rate of specific mutational signatures compared to older patients. These findings suggest age-related differences in Hodgkin lymphoma genetics and molecular features, which could impact… Continue reading Lymphomas in the Young and the Old: How Do They Differ?

Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models

AI SummaryThis study explores the use of immune isolation-enabled nanoencapsulation of donor T cells as a promising strategy for managing graft-versus-host disease (GVHD) and treating acute myeloid leukemia (AML) in preclinical models. The researchers crafted nanocapsules to encapsulate T cells, which were then transplanted into AML mice. The encapsulated T cells demonstrated a reduction in… Continue reading Immune isolation-enabled nanoencapsulation of donor T cells: a promising strategy for mitigating GVHD and treating AML in preclinical models

Distinct stabilization of the human T cell leukemia virus type 1 immature Gag lattice

AI SummaryThe content explains the distinct stabilization mechanism of the human T cell leukemia virus type 1 (HTLV-1) immature Gag lattice, as compared to other retroviruses. Cryo-electron tomography studies revealed that HTLV-1 uses a unique mechanism of Gag-Gag interactions for lattice formation, with the N-terminal domain of the capsid (CA) being the primary stabilizing component.… Continue reading Distinct stabilization of the human T cell leukemia virus type 1 immature Gag lattice

Durable efficacy with fixed‐duration BTKi and venetoclax for CLL

AI SummaryThis article discusses the durable efficacy of fixed-duration Bruton’s Tyrosine Kinase inhibitors (BTKi) and venetoclax for Chronic Lymphocytic Leukemia (CLL). The study highlights the long-lasting effectiveness of this treatment combination for CLL patients. The findings suggest promising results in managing CLL with a set treatment duration using BTKi and venetoclax.Cancer, Volume 130, Issue 19,… Continue reading Durable efficacy with fixed‐duration BTKi and venetoclax for CLL